Patients requiring anti-VEGF (vascular endothelial growth factor ) therapy for diabetic macular oedema (DME) can be reassured that their need for injections will most likely decrease over time. Associate Professor Jennifer Sun, from the Harvard Department of Ophthalmology and the Joslin Diabetes Centre, said a typical regimen might include 8-9 injections in year 1, two ...
Anti-VEGFs represent ‘a sea change’ in diabetic macular oedema
By Mardi Chapman
10 Jul 2018